- Case Study: Establishing a Patient Advocacy Council to Guide Strategic Launch Planning
A mid-size pharmaceutical company partnered with Herspiegel to establish a standing council of 30 patient advocates. This long-term engagement infused patient insights into strategic planning, enhancing relevance and trust across key functions. Read here.
- Article: Advancing Patient-Centered Medical Publications Through Publication Extenders
At ISMPP 2025, a clear imperative emerged: the future of medical publications reporting must be more inclusive, accessible, and patient-centered. Read the article here.
- Article: Generative AI in Publications Development: Innovation with Oversight
Artificial intelligence (AI) is rapidly influencing the future of medical publication development. Read about our findings in this article.
- Case Study: Optimizing Clinical Endpoints for Phase III Design
We helped our client update their primary endpoint (the CGI-I subscale) for their planned Phase III clinical study.
- Case Study: Elevating Investor Engagement in Early-Stage Therapeutic Development
We helped our client communicate key information about their portfolio and technology to help resonate with investors and support funding efforts. Read case study here.
- Article: Rare Disease Launch: Best Practices – Planning, Budget & Timing
The video outlines best planning, timing, and budgeting practices in rare disease product launches. Watch here.
- Article: Navigating success during a rare disease product launch
In this video, experts Kapil Raina, Chris Zealey, and Brian Williams, explore insights on successfully launching products in rare disease markets.
- Article: Rare Disease Product Launch: Parameters for Success
The video outlines key success factors in rare disease markets through the five P's: People, Product, Payers, Promotion, and Placement. Watch here.
- Article: Rare Disease Launch: What We Heard From CCOs
Gain insights from Chief Commercial Officers on launching in the rare disease market. Watch here.
- Case Study: Redefining the Treatment Paradigm in Mental Health
Our client was approaching the launch of a new product for treatment of a mental health disorder. Despite promising trial data, successful adoption of their therapy would be challenging for a number of reasons. Read the case study.
- Case Study: Pioneering Treatment Paradigm in Neurology
Discover how we assisted our client in positioning their therapy for optimal impact in the evolving landscape of steroid reduction and global treatment strategies.
- Case Study: Strategic Repositioning of a GI Market Leader Amidst Evolving Market Dynamics
Explore how we analyzed and refined our client's drug positioning across multiple indications to ensure market alignment and strategic coherence. Read the case study.
- Case Study: Communication Strategy for Novel MOA in Neurological Disorder
Our client aimed to apply a proven molecule to a new neurological disorder. We helped create a compelling narrative and cost-effective strategy to boost ROI. Read the case study.
- Case Study: Strategic Launch in a Rare Hematologic Disease
Learn how we navigated the challenges of launching a novel treatment in a rare hematologic disease to position our client's drug as a potential new standard of care. Read the full case study.
- Article: Rare Disease Landscape: Why You Need a Different Launch Playbook
Explore the rare disease landscape, focusing on patients' diagnostic and treatment challenges, competitive dynamics, and tailored launch strategies.
- Case Study: Development of a Scientific Platform for Biotech Client
Our biotech client was facing the challenge of introducing a new competitor into the market while simultaneously gaining a deeper understanding of their disease state. To navigate this complex scenario, they needed a strategic document that would serve as the foundation for both internal and external communications.
- Case Study: KOL Identification and Engagement Planning in Rare Disease Clinical Development
Our client, a leading biopharmaceutical company, sought to embark on a clinical development program within a new therapeutic area in the rare disease space. Read the case study.
- Article: Unveiling Insights: How KOLs Shaped a Groundbreaking Therapy’s Journey
A recent pivotal Phase 3 clinical trial marked a significant milestone for our client, a biopharmaceutical company, in their quest to introduce a novel treatment for major depressive disorder (MDD). Read more.
